Heidi Overton FDA Pick: What It Means for Approvals

The FDA has gone without a confirmed commissioner. Trump just named one — and by lunchtime a Republican senator called part of her record almost disqualifying.

Also in this one: Regeneron's Pasatru clears the FDA in an ultra-rare bone disease worldwide, SK Biopharmaceuticals settles its first Xcopri generic challenge, and SK Pharmteco cuts the ribbon on a pair of API plants in Ireland. Busy one. Let's get into it.

Welcome to The Pharma Closeout for Wednesday, August 19th. I'm Alex Mercer.

And I'm Maya Patel.

Heidi Overton is the President's nominee to run the FDA. Physician, doctorate in clinical investigation from Johns Hopkins, currently deputy director of the White House Domestic Policy Council. The number that frames this: three months. That's how long the agency has been without a confirmed commissioner, since Marty Makary resigned in May under White House pressure. Every filing timeline the industry is carrying right now runs through an agency operating under an acting chief.

Start with who said no.

That's the part people are skipping. Brad Wenstrup — Republican congressman, physician — was at one point the preferred candidate, and he declined. Kyle Diamantas, the acting commissioner, turned it down repeatedly. Trump asked him directly and he still said no, citing his young children and reservations about the role itself. Months of searching, candidates being interviewed as late as Tuesday, and the job lands on a White House insider because the outside candidates wouldn't take it.

The credentials are real. Medical degree out of New Mexico, the Hopkins doctorate, ran the health policy center at America First Policy Institute. What's missing is a record running anything at scale — and Bill Cassidy said exactly that within hours. Strong concerns. Lack of managerial experience for an organization already dealing with staffing and morale problems. Then he went past management: her active role in last week's vaccine executive order, in his words, that alone is almost disqualifying.

A sitting Republican, day one.

And that's the consequence for this industry. Cassidy is the same senator who delayed the CDC pick this month before Erica Schwartz squeaked through — he isn't the opposition, he's friction inside the majority. So here's the risk in plain terms. A vaccine-skeptical commissioner is a regulatory risk that concentrates on mRNA. Every mRNA platform program in oncology and immunology now carries an approval-timeline question that has nothing to do with the data package.

I'd push on "concentrates on mRNA." Commissioners don't sign approvals — review divisions do, and the reviewers on your file don't change on a confirmation vote. If you're modeling a BLA decision eighteen months out, a nominee's position on vaccine requirements is not in your critical path.

Fair on any single file. But she was standing behind the President in the Oval Office when he signed the childhood vaccine schedule order, and a commissioner decides what gets escalated, who sits on advisory committees, and which categories draw a second look. That's not the critical path. That's the variance around it.

Then say it that way, because the distinction is the whole story. Where a commissioner actually moves outcomes is staffing, advisory-committee composition, and the appeal route when a division and a sponsor disagree — and Cassidy just told you staffing and morale are the presenting problem before she even arrives. So widen the confidence interval on your review timelines. Don't move the point estimate.

Competitive read: if you run regulatory strategy, nothing changes at your review division tomorrow — but the leadership question doesn't clear until the Senate votes, and she's taking fire from both directions. One prominent MAHA figure called the pick a steep fall into the swamp, on the same day Kennedy called her a superstar. Watch the health committee. A second contested confirmation leaves this agency acting-led into the fall, and that's the environment your 2027 filings get planned in.

Maya, you'll like the second one better than the first. Shifting to the deal and pipeline side — SK Pharmteco cut the ribbon on two facilities at its Swords, Ireland campus. The one that matters is the kilo-scale plant for high-potency ingredients and ADC payloads, engineered for containment down to occupational exposure limits of ten nanograms per cubic meter. The second is a multi-purpose small-molecule plant that adds roughly twenty-six and a half cubic meters of reactor capacity.

Ten nanograms is the number.

And the payload suite is the one to read. Batch sizes of half a kilo to a kilo and a half sit precisely in the gap that strands ADC programs — the point where a payload has cleared early clinical supply and needs GMP material at commercial-ready containment. Nobody loses an ADC program on antibody supply. They lose eighteen months on the cytotoxic side, because the containment build is the long pole and you can't compress it.

Payload capacity, not antibody capacity.

Which is exactly the read for anyone with an ADC in the clinic and no captive high-potency site. European kilo-scale slots just got less scarce — and scarcity is what you've been paying for. That changes your leverage in the next supply negotiation, not the one after it.

On the regulatory side, SK Biopharmaceuticals settled its patent fight with MSN Laboratories over cenobamate — Xcopri in the U.S. Delaware litigation dismissed, MSN gets rights to launch a generic in the future subject to patent protection and agreed conditions, terms confidential. The structural point is what the dispute was actually about: follow-on patents, not composition-of-matter. SK says the settlement supports continued protection after that patent expires, and describes exclusivity as extending beyond October of that year.

And the franchise underneath it is real — 707 billion Korean won in 2025, about $480 million, up twenty-nine percent. This is the first settled challenge on the follow-on estate, which makes it the one that decides whether Xcopri has a cliff or a runway.

Settled isn't dated.

That's the discipline I'd apply. The company says itself that whether and when MSN launches depends on the U.S. approval process and on confidential terms neither side disclosed. So an entry date exists inside that agreement — you just don't have it, and "beyond October 2032" is the company's characterization, not a docket entry.

So what would change your read?

A launch date, or the Phase 3. There's a study running in primary generalized tonic-clonic seizures, and that expansion is the entire reason 2032 is worth fencing at all. If you're modeling this franchise, the label expansion is the asset and the settlement is only the fence around it. Price the expansion as the thing that has to land first, and carry the fence as undated — because an undated fence and a firm one are worth very different multiples.

Before we look ahead — the FDA approved Regeneron's Pasatru today for adults with fibrodysplasia ossificans progressiva. Roughly nine hundred cases worldwide, about two hundred twenty adult U.S. patients. Per the approval, it's the second drug cleared in the disease, after Ipsen's Sohonos.

The Optima data is strong, and this is where I'll spend my one explanation: in FOP, soft tissue converts to bone after flare-ups, and Pasatru blocks activin A upstream of that. At fifty-six weeks, new heterotopic ossification lesions fell ninety percent on the ten milligram per kilogram dose and ninety-four percent on the three milligram dose, respectively, versus placebo. Flare-ups fell eighty-nine percent on the high dose. Notice the asymmetry — the lower dose carried the lesion endpoint numerically better, the higher dose carried flare-ups. That's a dosing conversation, not a rounding artifact.

Regeneron shares gained following the approval. But two hundred twenty adult patients isn't a revenue story. It's a credibility story about what this company can get through a pivotal and a review.

Which is the read-through nobody puts in a press release. Regeneron got garetosmab across the line on a Phase 3 in a disease — targeted biologic, small pivotal, hard imaging endpoint. That's the same template the individualized neoantigen cancer-vaccine field is betting on to validate mRNA in oncology: prove mechanism in a defined population, then expand. Pasatru says this agency will approve on precision rather than volume — and that's the standard those mRNA oncology programs get measured against.

Looking ahead, three things. How fast the Senate health committee moves on Overton — pace matters as much as outcome. The Xcopri study in primary generalized tonic-clonic seizures. And Pasatru's launch mechanics into a two-hundred-twenty-patient population, where finding the patients is harder than selling to them.

I'd weight the confirmation math heaviest. Schwartz reached the CDC narrowly, and only after a delay. If Overton's process stretches the same way, this agency stays acting-led through the fall — and every sponsor with a contested review in that window is negotiating with an organization that has no confirmed authority above the division level.

What I'll be sitting with tonight is that dose split in Optima — the lower arm outperforming on lesions is the kind of detail that quietly writes the label and then writes prescribing practice for a decade. Have a good evening, everyone.

And that is your Pharma Closeout for Wednesday, August 19th — Heidi Overton headed for a Senate fight, Regeneron's Pasatru approved in FOP, SK Biopharmaceuticals fencing Xcopri out to 2032, and new payload capacity in Swords. A nomination, an approval, and a patent settlement inside one news cycle — this industry does not do quiet Wednesdays. Follow the show on Spotify, Apple Podcasts, or wherever you listen — tomorrow's briefing lands on its own.